ChiCTR2400088020 版本V1.0 版本创建时间2024/08/09 09:36:34 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400088020 

最近更新日期:

Date of Last Refreshed on:

2024-08-09 09:36:31 

注册时间:

Date of Registration:

2024-08-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

机器人甲状腺癌根治切除术与传统开放手术的回顾性对照研究

Public title:

A retrospective comparative study of robotic thyroidectomy and traditional open thyroidectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

机器人甲状腺癌根治切除术与传统开放手术的回顾性对照研究

Scientific title:

A retrospective comparative study of robotic thyroidectomy and traditional open thyroidectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

覃湘泉 

研究负责人:

范林军 

Applicant:

xiangquan Qin 

Study leader:

linjun Fan 

申请注册联系人电话:

Applicant telephone:

+86 183 2307 0397

研究负责人电话:

Study leader's
telephone:

+86 183 2307 0397

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

docqxq0927@163.com

研究负责人电子邮件:

Study leader's E-mail:

docqxq0927@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市沙坪坝区高滩岩正街30号

研究负责人通讯地址:

重庆市沙坪坝区高滩岩正街30号

Applicant address:

No. 30, Gaotanyan Zhengjie, Shapingba District, Chongqing

Study leader's address:

No. 30, Gaotanyan Zhengjie, Shapingba District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

400038

研究负责人邮政编码:

Study leader's postcode:

400038

申请人所在单位:

陆军军医大学第一附属医院(西南医院)

Applicant's institution:

The First Affiliated Hospital of Army Medical University (Southwest Hospital)

研究负责人所在单位:

陆军军医大学第一附属医院(西南医院)

Affiliation of the Leader:

The First Affiliated Hospital of Army Medical University (Southwest Hospital)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(B)KY2022214

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军陆军军医大学 第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Army Medical University, Chinese People's Liberation Army

伦理委员会批准日期:

Date of approved by ethic committee:

2022-11-04 00:00:00

伦理委员会联系人:

蒋璐灿

Contact Name of the ethic committee:

jiang lucan

伦理委员会联系地址:

重庆市沙坪坝区高滩岩正街30号

Contact Address of the ethic committee:

No. 30, Gaotanyan Zhengjie, Shapingba District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 183 2307 0397

伦理委员会联系人邮箱:

Contact email of the ethic committee:

docqxq0927@163.com

研究实施负责(组长)单位:

陆军军医大学第一附属医院(西南医院)

Primary sponsor:

The First Affiliated Hospital of Army Medical University (Southwest Hospital)

研究实施负责(组长)单位地址:

重庆市沙坪坝区高滩岩正街30号

Primary sponsor's address:

No. 30, Gaotanyan Zhengjie, Shapingba District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

西南医院

具体地址:

重庆市沙坪坝区高滩岩正街30号

Institution
hospital:

Southwest Hospital

Address:

No. 30, Gaotanyan Zhengjie, Shapingba District, Chongqing

经费或物资来源:

Source(s) of funding:

none

研究疾病:

甲状腺癌  

Target disease:

thyroid cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

分析甲状腺癌机器人与开放手术治疗对患者近远期安全性(相关并发症、复发率、生存率等)、社会经济效益等方面的差异。  

Objectives of Study:

To analyze the differences in short-term and long-term safety (related complications, recurrence rate, survival rate, etc.) and socioeconomic benefits between robotic and open surgery for thyroid cancer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

经穿刺活检后病理确诊为甲状腺癌,并于我科进行机器人或者开放甲状腺癌根治手术治疗的患者

Inclusion criteria

Patients who were pathologically diagnosed with thyroid cancer after needle biopsy and underwent robotic or open radical surgery for thyroid cancer in our department were enrolled

排除标准:

诊断不明确的病例或者未进行手术治疗的患者

Exclusion criteria:

Patients with uncertain diagnosis or without surgical treatment

研究实施时间:

Study execute time:

From 2024-09-01 00:00:00 To 2026-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-01 00:00:00 To 2025-03-31 00:00:00

干预措施:

Interventions:

组别:

机器人组

样本量:

1938

Group:

robotic group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

开放组

样本量:

7017

Group:

open group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

西南医院 

单位级别:

三甲 

Institution
hospital:

Southwest Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

甲状腺旁腺功能减退

指标类型:

主要指标

Outcome:

Hypoparathyroidism

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 12 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Case Record Form

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-08-09 09:36:31